Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study by Pedro Ferreira, João et al.
Effect of Eplerenone on Extracellular Cardiac Matrix Biomarkers in Patients With acute 
ST-elevation Myocardial Infarction without Heart Failure: Insights from the Randomized 
Double-Blind REMINDER Study 
 
João Pedro Ferreira, MD, PhD1,2; Kévin Duarte, Msc1; Gilles Montalescot, MD, PhD3; Bertram 
Pitt, MD4; Esteban Lopez de Sa, MD, PhD5; Christian W. Hamm, MD, PhD6; Marcus Flather, 
MD, PhD7; Freek Verheugt, MD, PhD8; Harry Shi, MD, PhD9; Eva Turgonyi, MD, PhD10; 
Miguel Orri, MD, PhD10; Patrick Rossignol, MD, PhD1; John Vincent, MD, PhD9; Faiez 
Zannad, MD1, PhD. 
 
1INSERM, Centre d’Investigations Cliniques Plurithématique 1433, INSERM U1116, 
Université de Lorraine, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France;  
2Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and 
Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal; 
3Institut de Cardiologie, Centre Hospitalier Pitié-Salpêtrière (AP-HP, ACTION Group, 
University Paris 6), 47 boulevard de l'Hôpital, 75013 Paris, France; 
4Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, USA; 
5Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain; 
6Kerckhoff-Klinik, Heart Clinic, Bad Nauheim, Germany; 
7Norwich Medical School, University of East Anglia, Norwich, UK; 
8Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands; 
9Pfizer Inc., New York, USA; 
10Pfizer Ltd, Tadworth, Surrey KT 20 7NS, UK; 
 
Contact to: 
Professor Faiez Zannad 
Centre d'Investigations Cliniques-INSERM CHRU de Nancy,  
Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu,  
4 Rue du Morvan, 54500 Vandoeuvre lès Nancy, France. 
Tel : +33 (0) 3 83 15 73 15 
Fax : +33 (0) 3 83 15 73 24 
Electronic address: f.zannad@chru-nancy.fr. 
 
Word-count: 3440 words (excluding abstract and references) 
 
 
 
Abstract 
Objective: Aldosterone stimulates cardiac collagen synthesis. Circulating biomarkers of 
collagen turnover provide a useful tool for the assessment of cardiac remodeling in patients with 
an acute myocardial infarction (MI).  
Methods: The REMINDER trial assessed the effect of eplerenone in patients with an acute ST-
elevation Myocardial Infarction (STEMI) without known heart failure (HF), when initiated 
within 24 h of symptom onset. The primary outcome was almost totally (>90%) driven by 
natriuretic peptide (NP) thresholds after 1-month post-MI (it also included a composite of 
cardiovascular death or re-hospitalization or new onset HF or sustained ventricular tachycardia 
or fibrillation or LVEF ≤40% after 1-month post-MI). This secondary analysis aims to assess 
the extracellular matrix marker (ECMM) levels with regards to: 1) patients` characteristics; 2) 
determinants; 3) and eplerenone effect. 
Results: Serum levels of ECMM were measured in 526 (52%) of the 1012 patients enrolled in 
the REMINDER trial. Patients with procollagen type III N-terminal propeptide (PIIINP) above 
the median were older and had worse renal function (p<0.05). Worse renal function was 
associated with increased levels of PIIINP (standardized β≈0.20, p<0.05). Eplerenone reduced 
PIIINP when the levels of this biomarker were above the median of 3.9 ng/mL (0.13±1.48 vs. -
0.37±1.56 ng/mL, p=0.008). Higher levels of PIIINP were independently associated with higher 
proportion of NP above the prespecified thresholds (HR=1.95, 95%CI=1.16-3.29, p=0.012). 
Conclusions: Eplerenone effectively reduces PIIINP levels when baseline values were above the 
median. Eplerenone may limit ECMM formation in post-MI without HF. 
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Introduction 
Acute myocardial infarction (AMI) is a major cause of deleterious cardiac remodeling 
harboring an increased risk for left ventricular dysfunction and heart failure (HF). The effect of 
adverse remodeling on cardiac structure and function assessed by routinely available imaging 
methods (such as cardiac ultrasound) and laboratorial results (such as natriuretic peptides) may 
detect only late stages of adverse remodeling and cannot assess if the myocardial changes are a 
consequence of impairment in the extracellular collagen matrix markers (ECMM) or in the 
cardiac myocytes1, 2. In this regard, circulating biomarkers of collagen turnover may provide a 
useful and validated tool to reliably assess this ECMM turnover, as demonstrated in patients 
with systolic dysfunction either in chronic heart failure with reduced ejection fraction (HF-REF) 
or post-MI1, 3, 4.  
The REMINDER (early eplerenone treatment in patients with acute ST-elevation 
myocardial infarction without heart failure) trial5 was designed to assess the impact of 
eplerenone on cardiovascular (CV) outcomes in patients with STEMI without known HF. This 
setting may allow to assess the impact of the mineralocorticoid receptor antagonist (MRA) 
eplerenone for limiting “myocardial fibrosis” in patients at risk for HF but without overt HF.  
Alterations of the ECMM and cardiac remodelling play a major role in the development 
and evolution of the cardiac alterations that lead to HF6. In this regard, several potential 
circulating biomarkers (BMs) for assessment of cardiac fibrosis have been proposed6, 7. 
Particularly, the BMs of ECMM formation measured in the REMINDER study were: 
procollagen type III N-terminal propeptide (PIIINP), collagen type I C-terminal telopeptide 
(ICTP), and procollagen type I N-terminal propeptide (PINP), and also Galectin-3.  Of these, 
the PIIINP (involved in the collagen biosynthesis) has been the most robustly associated with 
myocardial fibrosis and validated thoroughly8-10.  
 The main aims of this secondary analysis of the REMINDER trial are to assess the 
ECMM marker levels with regards to: 1) patients` characteristics; 2) factors associated with 
increased levels; 3) and eplerenone effect. 
 
Methods 
Study Design and Patient Population 
The design and main results of the REMINDER trial have been previously reported5 
and is registered at ClinicalTrials.gov with the number: NCT01176968. 
In short, the REMINDER trial was a randomized, placebo-controlled, double-blind trial, 
assigning 1012 patients with acute STEMI and without HF history to receive either eplerenone 
(25–50 mg once daily) or placebo (n =506 in each group) in addition to standard therapy. 
Eligible subjects were identified for inclusion following emergency room/ambulance evaluation 
and diagnosis of acute STEMI in the absence of a clinical diagnosis of HF. Randomization had 
to take place as early as possible following diagnosis and the first dose of study drug 
administered within 24 h of the onset of symptoms of acute MI and preferably within 12 h. The 
primary endpoint was the composite of CV mortality, re-hospitalization, or extended initial 
hospital stay due to diagnosis of HF, sustained ventricular tachycardia or fibrillation, ejection 
fraction ≤40% at 1-month or later post-randomization, or elevated BNP/NT-proBNP at 1-
month. Natriuretic peptide (NP) elevation was defined as BNP levels ≥200 pg/mL or NT-
proBNP values ≥450 pg/mL (in patients aged less than 50 years), ≥900 pg/mL (in patients aged 
50 to 75 years), or ≥1800 pg/mL (in patients older than 75 years). The primary endpoint 
occurred in 92 patients (18.2%) in the eplerenone group and in 149 patients (29.4%) in the 
placebo group (adjusted hazard ratio, HR [95% confidence interval, CI] =0.58 [0.45–0.76], p 
=0.0001). The primary endpoint was essentially (91%) driven by the NP thresholds that were 
higher in the placebo group. The “hard” endpoint of CV mortality or HF hospitalization or 
extended hospitalization due to HF occurred only in 9 (1.8%) patients in the eplerenone group 
vs. 13 (2.6%) patients in the placebo group which is largely underpowered to drive any 
conclusion on major CV events. Adverse event rates were low (<6%) and similar in both 
groups.  
This present substudy was conducted in the 526 patients participating in the 
REMINDER trial with ECMM measurements. The selection of patients in whom ECMM were 
measured was performed in a random fashion. In the present subanalysis the NP thresholds 
represented 92% (n=126) of the 137 recorded events. 
Blood samples for all the biomarkers of collagen turnover were analyzed in 1 
laboratory. Plasma NPs and other neurohormones were analyzed in different laboratories. 
A transthoracic echocardiogram was performed at the 6-month follow-up and at the end 
of study visit.   
Blood Sampling 
Blood samples were drawn at baseline (i.e., within the first 24h after STEMI diagnosis) 
and at 6 months of follow-up. All samples were centrifuged immediately at 3000 rpm for 10 
minutes and stored at -80°C until assay analysis. A minimum of 2 samples were available per 
patient: 1 at baseline and 1 at 6-month follow-up. All samples were transported to the central 
laboratory and assayed in 1 batch. 
Laboratory Analysis of the Biomarkers  
The measured “collagen” biomarkers were: PIIINP, ICTP, PINP, and Galectin-3. All 
assays were performed by technicians blinded to clinical data and subject randomization. 
Commercial radioimmunoassays (Orion Diagnostica®) were used to measure PIIINP, ICTP, 
PINP, and Galectin-3). The sensitivity (lowest concentration different from zero) was 0.3 ng/mL 
for PIIINP, 2.0 ng/mL for PINP, 0.4 µg/L for ICTP, and 3 ng/mL for Galectin-3. Normal serum 
ranges were provided by the assay manufacturer were 2.3 to 6.3 ng/mL for PIIINP; 19 to 83 
ng/mL for PINP in women and 22-87 ng/mL in men; 2.1 to 5.6 ng/mL for ICTP in women and 
2.1 to 5.0 ng/mL in men; and <22.1 ng/mL for Galectin-3. Inter-assay variations for PIIINP, 
PINP, ICTP, and Galectin-3 were <12% and their intra-assay variations were <10%. 
Statistical Analysis 
 Continuous variables were all inspected by histogram visualization and described as 
mean ± standard deviation if normally distributed or median (percentile 25-75) if distribution was 
skewed. Categorical variables were described as absolute numbers (n.) and proportions (%). The 
studied biomarkers were divided by their median values in order to be compared by “lower” vs. 
“higher” values. Normality assumptions were verified by histogram assessment. Missing values 
proportion was overall low and no multiple imputation was performed.  
 Linear regression models were performed to assess the relation between the studied 
biomarkers (as outcome variables) and several explanatory variables selected from demographic 
(age, gender), clinical (heart rate, systolic blood pressure, body mass index), laboratorial 
(estimated glomerular filtration rate, hemoglobin, sodium, potassium, urea, albumin, total 
bilirubin, alanine aminotransferase, aldosterone, cortisol), medical history (diabetes, 
hypertension, atrial fibrillation, previous myocardial infarction), concomitant treatments 
(angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, lipid 
lowering therapies, diuretics), and biomarker (natriuretic peptides, troponins) variables. Linear 
regression assumptions were met. In particular normality was handled by Log2 transformation of 
skewed variables and “normality” re-verification on histogram. Colinearity was assessed by 
colinearity tables and tolerance verification (diastolic blood pressure and aspartate 
aminotransferase were excluded from the models due to high correlation [>0.7] with systolic 
blood pressure and alanine aminotransferase, respectively). Observed versus expected 
probability P-P padronized residuals regression plot was checked for linearity assessment and 
plot of padronized residuals versus predicted padronized values was also checked for 
heteroscedasticity exclusion (all values were within the 3 to -3 range). The first model was 
entered with 200x bootstrapping, then a backward selection model was processed. The variables 
retained in the final model with a p-value <0.05 are presented in the tables. Due to a high 
proportion of missing values (≈70%), natriuretic peptides (median) were ran (as independent 
variable) in individual models, but they were not significantly associated with any of the 
outcome variables. Due to imprecision in the associations regarding natriuretic peptides, we 
present in tables any association with a p-value of less than 0.1. 
To determine predictors of having a “fibrosis markers” above the median we developed 
logistic regression models. These models used clinical and laboratory variables with a p-value 
<0.2 as entry criteria. The first model was a forward conditional model eliminating 
progressively the variables with weaker association and retaining in the final model those 
variables with a p <0.05. The second model used a stepwise backward selection process. Both 
models provided similar final results.  Logistic regression assumptions were checked and 
multicollinearity excluded. Linear relationship between continuous independent variables and 
the logit transformation of the dependent variable was verified by plotting the means vs. the β 
estimates in quintiles. All presented models met the logistic regression assumptions. The 
computation of ECMM on their median values was not a prespecified analysis. 
The natriuretic peptide threshold outcome was analyzed by Cox proportional hazard 
regression models. An interaction term between the biomarker of interest and treatment 
allocation (as “dummy” variable) was tested within the Cox model. In the multivariable models, 
the covariates for adjustment were chosen from demographic (age and gender), clinical (heart 
rate, body mass index, diabetes, hypertension, previous myocardial infarction), laboratorial 
(estimated glomerular filtration rate determined by the CKD-EPI formula11 and aspartate 
aminotransferase), and pharmacological (ACEi/ARBs, β-blockers, diuretics, and treatment 
allocation i.e. eplerenone or placebo) variables. The “rule of thumb” of 1 variable per 10 events 
was met. Proportional hazard assumption was verified graphically using "log-log" plots. The 
studied variables had a linear association with the outcome. 
We also performed a Principal Components Analysis (PCA) in order to determine 
which variable(s)/biomarker(s) that explain the largest proportion of the variability in the data. 
We used the direct oblimin rotation method and fixed the number of retained components to 
two. 
Additional analysis of covariance (one-way ANCOVA) were also performed to assess 
the treatment effect on PIIINP levels adjusted on age, gender and estimated glomerular filtration 
rate. 
All analysis were performed using R® software (The R Foundation for Statistical 
Computing). 
 
Results 
Baseline Characteristics of the Study Population 
 The characteristics of the population analyzed in the present study are depicted 
in Table 1, where the characteristics of the patients with levels of PIIINP below vs. above the 
median are also described. Patients with PIIINP levels above the median were older, had lower 
eGFR, higher ICTP and PINP levels (all p <0.05). Table 1. The comparison of patients 
according to the median levels of Galectin-3, ICTP, PINP, and Aldosterone are presented in the 
Supplemental Material Tables 1 to 4. The patients` characteristics according to the median 
PIIINP levels at 6-months are presented in the Supplemental Table 5.  
 The characteristics of the patients with vs. without ECMM markers measurements, as 
well as the characteristics of the patients randomized to eplerenone or placebo, are well 
balanced. Supplemental Table 6 and Supplemental Table 7. The correlation between ECMM 
markers is generally weak, with higher correlations between PIIINP and ICTP (=0.29). 
Supplemental Table 8.  
The baseline levels of the ECMM markers did not differ between eplerenone and 
placebo groups. Supplemental Table 9. 
Linear and Logistic regression models 
 Linear regression models using ECMM marker as outcome variables are presented in 
Table 2. The proportion of the total variability in the outcome variables was little explained by 
the variables inserted in the models, ranging from 11% (adjusted R2 =0.11) for PIIINP to 23% 
for Galectin-3 (adjusted R2 =0.23). The levels of PIIINP were likely to increase in the context of 
lower eGFR (β =0.23), higher heart rate (β =0.15), and higher total bilirubin (β =0.11). Galectin-
3 levels were likely to increase in the context of lower eGFR (β =0.34), higher cortisol and 
aldosterone levels (β =0.18 and β =0.13, respectively), and higher ALT (β =0.12). Levels of 
ICTP possibly also increase in the context of worse renal function, higher BMI, bilirubin, heart 
rate, and diuretic use. PINP levels were likely to be higher in females, and decrease with ageing, 
aldosterone, beta-blockers use, hypertension and diabetes history. Table 2. 
Logistic regression models (using ECMM markers above the median as reference) are 
presented in the Supplemental Table 10. and show similar associations to those observed in the 
linear regression models.  
Eplerenone Effect and Biomarkers 
  Eplerenone decreased PIIINP levels (from baseline to 6 months) when the baseline 
PIIINP levels were above the median of 3.9 ng/mL (absolute Δ PIIINP =0.13±1.48 in the 
placebo group vs. -0.37±1.56 in the eplerenone group; p =0.008). Figure 1 and Table 3. PINP 
levels were also decreased by eplerenone treatment when PINP baseline values were above the 
median. Table 3. As expected feedback mechanism eplerenone treatment increased aldosterone 
levels. Supplemental Table 11. 
 An analysis of covariance (one-way ANCOVA) was also performed to assess the 
eplerenone effect on PIIINP levels according to their baseline “median” value adjusted on age, 
gender and estimated glomerular filtration rate, providing overlapping results with those 
presented in univariate analysis. Supplemental Table 12. 
Natriuretic Peptide Associations 
 The NP driven primary outcome associations are depicted in the Table 3. Linear PIIINP 
and Galectin-3 were independently associated with the NP thresholds outcome (HR; 95%CI 
=1.95; 1.16-3.29; p =0.012 and 2.21; 1.49-3.28; p <0.001, respectively), whereas ICTP and 
PINP were not. Table 3.  The associations considering the biomarkers median levels and also 
those of aldosterone are presented in the Supplemental Table 13. 
 Eplerenone effect did not vary by baseline median ECMM levels (i.e. no significant 
“interactions” were found). Figure 2.  
Principal Components 
 The PCA identified PIIINP as explaining the majority of the variance in the data 
(38.1%), followed by ICTP (25.7%); PIIINP was also the first component to be retained after 
oblimin rotation (=0.75), followed by ICTP (=0.72). 
 
Discussion 
This is the first study describing mid-term kinetics of ECMM collagen biomarkers in 
patients with acute MI without overt HF. In the present manuscript, we demonstrate that higher 
levels of ECMM markers are partially dependent on factors such as renal function, heart rate 
and age. Importantly, eplerenone independently reduced the levels of PIIINP and PINP when 
these were above the median. These findings suggest that MRAs can limit the “pro-fibrotic” 
ECMM deposition and may have a role in limiting adverse cardiac remodelling independently 
of age, gender or renal function.  
Tissue repair through the synthesis of new ECMM by fibroblasts may be beneficial, 
particularly after a MI. However, prolonged activation of this process results in excess scar 
tissue formation and increased ECMM deposition, leading to an “excessive fibrosis” pattern that 
may severely compromise the myocardial tissue and impair electrical conduction favoring the 
advent of arrhythmia, particularly atrial fibrillation12. Fibrosis is itself a “dynamic tissue”13 in 
which collagen synthesis is an ongoing process involving metabolically active myofibroblasts12. 
Serum PIIINP has been found to be correlated to myocardial collagen type III in HF patients of 
ischemic etiology and idiopathic dilated cardiomyopathy (DCM)9, 10. Collagen scar formation 
after acute MI causing left ventricular systolic dysfunction could also be quantified by 
measurements of serum PIIINP concentrations14. Moreover, in patients with DCM the reduction 
of the myocardial collagen achieved by the treatment with the MRA spironolactone was also 
accompanied by a significant reduction in the serum levels of PIIINP9. In HF-REF patients with 
severe symptoms (findings from the Randomized Aldactone Evaluation Study: RALES), higher 
baseline PIIINP (levels superior to the median of 3.9 ng/mL) were associated with increased 
mortality rates (HR; 95%CI =2.36; 1.34-4.18) and PIIINP levels decreased in spironolactone 
treated patients from baseline to 6 months (whereas remained stable in placebo-treated patients). 
Of notice, in this subanalysis of the RALES trial the death rate reduction achieved by 
spironolactone treatment was only observed in patients with PIIINP levels above the median, 
whereas it was “neutral” in patients with PIIINP levels below the median (HR; 95%CI = 0.44; 
0.26–0.75 vs. 1.11; 0.66–1.88). In post-MI patients with HF-REF (findings from the Eplerenone 
Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study: EPHESUS)3, 
eplerenone treatment also consistently reduced PIIINP levels. In 134 patients with acute anterior 
STEMI a strategy of early aldosterone blockade with intravenous potassium canrenoate (the 
active metabolite of spironolactone) improved LVEF and reduced LV end-diastolic volume in 
comparison to controls. In this study, cardiac aldosterone extraction was suppressed and the 
plasma PIIINP levels were also significantly reduced in the aldosterone antagonist group15. All 
these findings overlap, to a great extent, those reported in the present REMINDER trial 
subanalysis, in which only patients with PIIINP levels above the median of 3.9 ng/mL had 
significant reduction of this biomarker. 
The median baseline levels of PIIINP in the REMINDER trial patients were similar to 
those reported in post-MI patients from EPHESUS (≈4.2 ng/mL) and HF patients from RALES 
(≈3.9 ng/mL), and lower than those reported in a setting of dilated cardiomyopathy patients 
(≈6.1 ng/mL)10, suggesting that patients with dilated cardiomyopathy have may have higher 
collagen turnover and ECMM matrix formation in concordance to the severity of disease 
presentation and prognosis. 
ICTP and Galectin-3 were not reduced by eplerenone treatment. Galectin-3 is a binding 
protein related to the collagen deposition of fibroblasts that is likely upregulated by the renin-
angiotensin-aldosterone system (RAAS)16, 17, but its direct correlation to the extent of cardiac 
fibrosis is lacking18. In the present study aldosterone and cortisol were slightly associated to 
Galectin-3 levels, suggesting that the RAAS may have a role for Galectin-3 activation also in 
the post-MI without HF context.  The association of ICTP to histologically proven myocardial 
fibrosis has also been inconclusive, and this molecule also does not seem to respond to MRA 
therapy in other contexts9, 10. Whether PINP is associated (or not) with myocardial fibrosis is 
unknown6, 8, and its associations to morbidity and mortality outcomes are also lacking1, 3. In the 
present analysis PINP levels decrease with ageing, aldosterone, hypertension and diabetes and 
were also reduced by eplerenone as compared to placebo. These ECMM fibrosis markers are 
not “heart-specific” and are present in other organs such as the kidney and liver19, the present 
analysis also offers insight in this regards, since variables such as eGFR, bilirubin and ALT are 
often retained in the final linear regression models as associated to the studied ECMM markers. 
Moreover, in some populations (e.g. hypertrophic cardiopathy) ECMM were not correlated to 
myocardial collagen deposition7, hence in the present analysis we cannot conclude that “cardiac 
fibrosis” was reduced by MRA, we can only state that some markers associated with collagen 
turnover were reduced by eplerenone treatment.   
Importantly, in the REMINDER trial several biomarkers were studied for research 
purposes. However, in clinical practice this is unlikely to be feasible. The PCA analysis 
demonstrates that PIIINP is also the biomarker that accounts for the greatest proportion of the 
variability in the data; therefore, it should be the biomarker to be used in this setting. 
  In resume, the results of our study with eplerenone are consistent with and extend the 
results of previous experimental and clinical observations with aldosterone antagonists in HF 
and after MI, and suggest that the beneficial effect of aldosterone antagonists on ECMM 
remodeling may contribute to the clinical benefits of this therapy. 
 Clinical and Research Implications 
A strategy of early aldosterone antagonism using potassium canrenoate in the first 
health-care contact for a MI (even without potassium or creatinine results were made available), 
followed by oral spironolactone was performed in the ALBATROSS trial (Early Aldosterone 
Blockade in Acute Myocardial Infarction). This “open-label” trial enrolled 1603 acute MI 
patients (STEMI and NSTEMI) to MRA or “standard therapy”, and did not show significant 
between-group differences regarding the primary outcome of death, resuscitated cardiac arrest, 
significant ventricular arrhythmia, indication for implantable defibrillator, or new or worsening 
HF at 6-month follow-up. Of notice, the death rate (non-prespecified exploratory outcome) was 
significantly lower in the STEMI subgroup (n =1229; HR; 95%CI =0.20; 0.06-0.70; p for 
interaction =0.01)20. However, it should be highlighted that both REMINDER and 
ALBATROSS were largely underpowered to detect significant treatment effect differences in 
morbidity and mortality. In ALBATROSS, the primary outcome occurred in only 95 (11.8%) 
and 98 (12.2%) patients in the treatment and control groups, respectively, and considering the 
same events in REMINDER the proportion was even lower (as described in the Methods 
section). The event rate would have been insufficient to ascertain treatment differences event if 
these trials had been performed together. The post-MI CV mortality and severe LV systolic 
dysfunction event rate has been declining steadily due to improvements in reperfusion times and 
techniques, and concomitant treatments, including devices. However, adverse remodelling still 
occurs thoroughly, leading to high and apparently unchanged rates of HF21. Designing an event-
driven trial in the setting of low event-rates is challenging as it requires several thousands of 
patients, a complex structure and unaffordable costs (especially for investigator-initiative trials). 
Hence, using clinically meaningful endpoints22 such as NPs and measures of myocardial 
remodelling (e.g. LVEF, LV volumes, strain analysis, or magnetic resonance imaging) may 
shorten the sample size to a few hundreds of patients and allow to determine the treatment 
effect. From this point of view, STEMI patients without HF with the characteristics of those 
enrolled in the REMINDER trial benefit from early introduction of eplerenone treatment as it 
decreases NPs, that are also a sensitive and specific marker of HF. Altogether, these findings 
suggest that MRAs may be an important therapy for HF prevention in post-MI. To date no data 
on biomarkers from the ALBATROSS trial have been made available, but do to its 
pharmacologic characteristics, intravenous potassium canrenoate may be interest in the MI 
setting due to its rapid onset of action (<30 min) reaching high plasma concentrations, whereas 
eplerenone may take up to 2 hours and spironolactone more than 24 hours, both reaching much 
lower plasma concentrations23, 24, and making these oral drugs less interesting when a rapid 
aldosterone blockade is required. 
The ECMM marker PIIINP has shown reproducible results and may be useful for trials 
with adaptive design where “responders” to therapy may be better selected along the trial based 
on the levels of this marker. However, “situation-specific” thresholds should be better 
determined and these assumptions require prospective validation. 
 
Limitations 
Several limitations should be noticed in the present analysis. First, this is a prespecified 
secondary analysis of the REMINDER trial, however the computation of ECMM on their 
median values was not prespecified in the protocol and some of the associations reported herein 
may result from multiple testing chance findings. Moreover, no validation cohort is available at 
this moment to reproduce these results, but this also strengthens the originality of the present 
work. Additionally, the characteristics of the patients analyzed herein are similar to those 
without ECMM markers determination, suggesting that randomization was well-balanced and 
that these results may be generalizable to the entire population of the trial. To detect a 0.3 
ng/mL difference in Log PIINP levels between eplerenone and placebo groups assuming a Log 
standard deviation of 0.4 ng/mL, a sample size of 76 patients (38 per group) would be required 
for a 90% power and an alpha of 5%. Hence this study was also adequately powered to detect 
differences in biomarker levels by treatment allocation. Second, this study does not allow to 
thrive conclusions on major adverse cardiovascular events, but such a study in this population is 
also unlikely to be performed due to a low event rate in this population (as explained in the 
above section). Third, no baseline/randomization transthoracic echocardiogram was performed, 
hence we cannot provide association between these markers and the baseline echocardiographic 
variables. Moreover, echocardiographic changes (from baseline to 6 months) cannot be 
computed in the present dataset either. These parameters could also provide information on 
cardiac remodelling. Fourth, no cardiac magnetic resonance imaging (MRI) was performed, this 
exam could provide useful information on myocardial fibrosis and would allow to assess the 
correlation between myocardial fibrosis and circulating ECMM in this population. In a previous 
report from 50 patients with hypertrophic cardiopathy (compared to 25 controls) the cardiac 
contribution to peripheral levels of byproducts of collagen synthesis was insignificant and 
peripheral levels of these biomarkers did not accurately reflect myocardial collagen content (as 
evaluated by cardiac MRI) in those patients7. Fifth, information regarding vessel involvement 
and lesions extension is not available in the dataset, and this could also influence the levels of 
ECMM. Sixth, ECMM were only measured at baseline and 6 months, hence we could not 
explore the kinetics of these biomarkers in the early post-MI period. Lastly, renal function is 
associated with the concentrations of ECMM in this context as is likely to be one of the 
strongest variables driving these markers` concentration in the present context, this reinforces 
the need for caution in interpreting these results as they may not reflect cardiac collagen 
turnover. 
 
Conclusions 
This is the first study describing mid-term kinetics of ECMM collagen biomarkers in 
patients with acute MI without overt HF. Eplerenone independently reduced PIIINP levels at 6 
months when the baseline values were above the median of 3.9 ng/mL. These findings suggest 
that MRAs can limit the “pro-fibrotic” ECMM deposition. 
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Table 1. Baseline (randomization) Characteristics of the Study Population with available 
“fibrosis biomarkers” and comparison with regards to median PIIINP levels (comparison 
according to the median values of the other biomarkers are presented in the Supplemental 
Material) 
Variables N Total PIIINP ≤3.9 ng/mL PIIINP >3.9 ng/mL p-value 
Demographics 
Age (years) 526 57.7 ± 10.7 56.7 ± 10.1 58.6 ± 11.2 0.039 
Female sex, n. (%) 526 99 (18.8 %) 44 (16.7 %) 55 (21.0 %) 0.22 
White race, n. (%) 526 507 (96.4 %) 251 (95.1 %) 256 (97.7 %) 0.13 
Clinical      
Heart rate (bpm) 518 72.7 ± 15.8 71.5 ± 15.4 73.9 ± 16.2 0.091 
SBP (mmHg) 526 125.5 ± 17.6 125.5 ± 18.0 125.5 ± 17.3 0.99 
DBP (mmHg) 526 76.2 ± 11.6 76.2 ± 12.4 76.2 ± 10.7 0.96 
BMI (Kg/m2) 526 27.9 ± 4.1 27.7 ± 4.1 28.0 ± 4.1 0.39 
Laboratory      
eGFR (ml/min/1.73m2) 526 87.3 ± 17.5 90.1 ± 16.3 84.5 ± 18.4 <0.001 
Urea (mg/dL) 519 15.9 ± 5.2 15.5 ± 4.5 16.3 ± 5.7 0.078 
Serum potassium (mmol/L) 526 4.1 ± 0.5 4.0 ± 0.4 4.1 ± 0.5 0.54 
Serum sodium (mmol/L) 526 138.6 ± 3.0 138.3 ± 2.9 138.9 ± 3.2 0.040 
Hemoglobin (g/dL) 525 14.3 ± 1.4 14.4 ± 1.3 14.2 ± 1.5 0.19 
Albumin (g/dL) 414 4.0 ± 0.5 4.1 ± 0.4 4.0 ± 0.6 0.36 
AST (IU/L) 481 50.0 (27.0 - 139.2) 54.3 (28.0 - 151.0) 45.0 (25.0 - 132.0) 0.16 
ALT (IU/L) 493 32.4 (21.0 - 49.0) 33.0 (23.0 - 48.6) 31.8 (20.0 - 50.0) 0.46 
Total bilirubin (mg/dL) 450 0.6 ± 0.3 0.6 ± 0.3 0.6 ± 0.3 0.51 
Aldosterone (mmol/L) 525 0.2 (0.1 - 0.3)  0.2 (0.1 - 0.3) 0.2 (0.1 - 0.3) 0.23 
Medical History      
Previous MI, n (%) 526 31 (5.9 %) 12 (4.5 %) 19 (7.3 %) 0.20 
Hypertension, n (%) 526 244 (46.4 %) 119 (45.1 %) 125 (47.7 %) 0.60 
Diabetes, n (%) 526 65 (12.4 %) 30 (11.4 %) 35 (13.4 %) 0.51 
Atrial fibrillation, n (%) 526 8 (1.5 %) 2 (0.8 %) 6 (2.3 %) 0.18 
Concomitant treatments at randomization 
ACEi/ARBs, n (%) 526 349 (66.3 %) 175 (66.3 %) 174 (66.4 %) 1.00 
β-blockers, n (%) 526 373 (70.9 %) 183 (69.3 %) 190 (72.5 %) 0.44 
Lipid lowering agents, n (%) 526 516 (98.1 %) 257 (97.3 %) 259 (98.9 %) 0.34 
Diuretics, n (%) 526 39 (7.4 %) 16 (6.1 %) 23 (8.8 %) 0.25 
PCI or Thrombolysis, n (%) 526 456 (86.7 %) 223 (84.5 %) 233 (88.9 %) 0.001 
Randomized to eplerenone, n (%) 526 266 (50.6 %) 136 (51.5 %) 130 (49.6 %) 0.73 
Biomarkers 
BNP (ng/dL) 51 103.2 (58.0 - 225.0) 104.6 (59.5 - 214.5 93.6 (43.0 - 303.5) 0.73 
NT-pro BNP (ng/dL) 114 262.1 (81.0 - 769.6) 262.1 (76.0 - 759.9 258.0 (138.2 - 988.8) 0.43 
NPs above the median, n (%) 165 82 (49.7 %) 47 (50.0 %) 35 (49.3 %) 1.00 
Troponin I (ng/dL) 281 6.4 (0.5 - 45.5) 6.8 (0.7 - 50.0) 5.8 (0.3 - 40.5) 0.24 
Troponin T (ng/dL) 210 0.5 (0.1 - 2.8)  0.4 (0.1 - 2.1) 0.9 (0.1 - 3.2) 0.063 
Troponins above the median, n (%)  491 245 (49.9 %) 119 (48.8 %) 126 (51.0 %) 0.65 
PIIINP (ng/mL) 526 3.9 (3.3 - 4.7) 3.3 (2.5 - 3.6) 4.7 (4.3 - 5.3) <0.001 
Galectin-3 (ng/mL) 523 11.9 (9.6 - 15.8) 12.0 (9.5 - 16.0) 11.8 (9.7 - 15.1) 0.80 
ICTP (µg/L) 526 3.7 (3.0 - 4.5) 3.3 (2.8 - 3.9) 4.0 (3.4 - 4.9) <0.001 
PINP (ng/mL) 526 31.0 (23.0 - 42.0) 28.5 (21.0 - 39.0) 34.0 (24.0 - 45.0) <0.001 
Study outcome 
Primary composite endpoint* 526 137 (26.0 %) 59 (22.3 %) 78 (29.8 %) 0.059 
Legend: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; 
eGFR, estimated glomerular filtration rate; AST, aspartate amino-transferase; ALT, alanine 
amino-transferase; ACEi/ARBs, angiotensin converting enzyme inhibitors/angiotensin receptor 
blockers; PCI, percutaneous coronary intervention; BNP, brain natriuretic peptide; NT-pro 
BNP, N-terminal pro brain natriuretic peptide; NPs, natriuretic peptides; PIIINP, procollagen 
type III N-terminal propeptide; ICTP, type I collagen C-terminal telopeptide; PINP, procollagen 
type I N-terminal propeptide. 
*CVM or re-hospitalization or new onset HF or sustained ventricular tachycardia or fibrillation 
or LVEF ≤40% after 1-month post-MI or BNP above 200 pg/mL or NT-proBNP above 450 
pg/mL (in patients aged below 50) or above 900 pg/mL (in patients aged 50 to 75 years), or 
above 1800 pg/mL (in patients older than 75 years) after 1-month post-MI. 
Biomarkers groups are based on the median values (i.e. below vs. above the median). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table 2. Linear regression models for baseline (randomization) Extra-cellular Matrix Markers as 
dependent variables 
Biomarkers / Final Models Adjusted R2 Standardized β Non-standardized 
coefficient (95% CI) 
 p-value 
Log PIIINP 
Overall model fit 0.11 - - <0.001 
Constant - - 1.26 (0.95 to 1.58) <0.001 
eGFR (per 10 ml/min decrease) - 0.23 0.05 (0.03 to 0.07) <0.001 
Heart rate (per 10 bpm increase) - 0.15 0.04 (0.01 to 0.06) 0.003 
Total Bilirubin (per 1 mg/dL increase) - 0.11 0.14 (0.03 to 0.26) 0.018 
ACEi/ARBs (yes) - -0.09 -0.10 (-0.19 to -0.00) 0.049 
Log Galectin-3 
Overall model fit 0.23 - - <0.001 
Constant - - 2.40 (1.83 to 2.97) <0.001 
eGFR (per 10 ml/min decrease) - 0.34 0.07 (0.05 to 0.09) <0.001 
Log Cortisol (per 1 Log unit increase) - 0.18 0.10 (0.03 to 0.17) 0.004 
Log Aldosterone (per 1 Log unit increase) - 0.13 0.08 (0.01 to 0.16) 0.027 
Log ALT (per 1 Log unit increase) - 0.12 0.07 (0.01 to 0.13) 0.019 
Log ICTP 
Overall model fit 0.14 - - <0.001 
Constant - - 2.11 (1.39 to 2.83) <0.001 
eGFR (per 10 ml/min decrease) - 0.24 0.05 (0.03 to 0.07) <0.001 
Body Mass Index (per 5 kg/m² increase) - 0.12 0.01 (0.00 to 0.02) 0.022 
Total Bilirubin (per 1 mg/dL increase) - 0.11 0.13 (0.00 to 0.25) 0.045 
Heart rate (per 10 bpm increase) - 0.10 0.02 (0.00 to 0.05) 0.040 
Diuretics (yes) - 0.10 0.15 (0.00 to 0.29) 0.050 
Log ALT (per 1 Log unit increase) - -0.12 -0.07 (-0.13 to -0.01) 0.026 
Log Cortisol (per 1 Log unit increase) - -0.11 -0.06 (-0.12 to -0.00) 0.036 
Log PINP 
Overall model fit 0.12 - - <0.001 
Constant - - 3.68 (3.37 to 4.00) <0.001 
Gender (female) - 0.16 0.19 (0.07 to 0.31) 0.003 
Age (per 10-year increase) - -0.16 -0.07 (-0.12 to -0.02) 0.004 
Log Aldosterone (per 1 Log unit increase) - -0.16 -0.12 (-0.20 to -0.05) 0.002 
β-blockers (yes) - -0.13 -0.18 (-0.32 to -0.04) 0.011 
Hypertension history (yes) - -0.12 -0.11 (-0,205 to -0,012) 0.027 
Diabetes (yes) - -0.12 -0.17 (-0.31 to -0.02) 0.026 
Legend: eGFR, estimated glomerular filtration rate; ACEi/ARBs, angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers; ALT, alanine aminotransferase; PIIINP, 
procollagen type III N-terminal propeptide; ICTP, type I collagen C-terminal telopeptide; PINP, 
procollagen type I N-terminal propeptide. 
 
 
 
 
 
 
 
Table 3. Treatment effect on Extra-cellular Matrix Markers according to their baseline “median” 
levels 
 
Legend: Δ, delta: 1) absolute =6 month value – baseline value, 2) relative =(6 month value – 
baseline value)/baseline value; PIIINP, procollagen type III N-terminal propeptide; ICTP, type I 
collagen C-terminal telopeptide; PINP, procollagen type I N-terminal propeptide. 
 
 
 
 
 
 
Biomarker variable Placebo Eplerenone p-value 
PIIINP >3.9 ng/mL    
Absolute Δ PIIINP 0.13±1.48 -0.37±1.56 0.008 
Relative Δ PIIINP 0.04±0.29 -0.05±0.26 0.011 
PIIINP ≤3.9 ng/mL    
Absolute Δ PIIINP 0.84±1.22 0.81±1.12 0.84 
Relative Δ PIIINP 0.39±0.80 0.40±0.87 0.89 
Galectin-3 >11.9 ng/mL    
Absolute Δ Galectin-3 -5.06±9.07 -4.17±8.29 0.42 
Relative Δ Galectin-3 -0.22±0.30 -0.17±0.27 0.19 
Galectin-3 ≤11.9 ng/mL    
Absolute Δ Galectin-3 0.32±2.12 0.81±2.60 0.091 
Relative Δ Galectin-3 0.05±0.23 0.11±0.30 0.058 
ICTP >3.7 µg/L    
Absolute Δ ICTP -0.16±1.71 -0.28±1.74 0.58 
Relative Δ ICTP -0.01±0.34 -0.03±0.33 0.76 
ICTP ≤3.7 µg/L    
Absolute Δ ICTP 0.55±0.88 0.48±1.07 0.54 
Relative Δ ICTP 0.21±0.34 0.24±0.80 0.75 
PINP >31 ng/mL    
Absolute Δ PINP -4.02±17.66 -8.27±14.99 0.041 
Relative Δ PINP -0.05±0.37 -0.17±0.30 0.008 
PINP ≤31 ng/mL    
Absolute Δ PINP 6.83±11.46 5.61±10.22 0.35 
Relative Δ PINP 0.37±0.63 0.34±0.75 0.75 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Natriuretic peptide thresholds outcome associations for the studied Extra-cellular 
Matrix Markers 
Biomarkers Model 1 
HR (95%CI) 
p-value Model 2 
HR (95%CI) 
p-value Model 2 
C-index 
“Linear” Models 
Log PIIINP (per 1 Log unit increase) 2.23 (1.34-3.70) 0.002 1.95 (1.16-3.29) 0.012 0.67 
Log Galectin-3 (per 1 Log unit increase) 2.79 (2.00-3.88) <0.001 2.21 (1.49-3.28) <0.001 0.71 
Log ICTP (per 1 Log unit increase) 1.26 (0.77-2.07) 0.35 0.92 (0.57-1.47) 0.71 0.66 
Log PINP (per 1 Log unit increase) 0.72 (0.51-1.01) 0.057 0.76 (0.53-1.09) 0.14 0.67 
Model 1: adjusted on treatment “random” allocation (i.e. eplerenone or placebo as “dummy” 
variable). All tested “interactions” between “linear” biomarker*treatment allocation were non-
significant (p >0.1). 
Model 2: adjusted on age, gender, heart rate, body mass index, estimated glomerular filtration 
rate, aspartate aminotransferase, diabetes, hypertension, previous myocardial infarction, 
ACEi/ARBs, β-blockers, diuretics, and treatment allocation. 
Legend: PIIINP, procollagen type III N-terminal propeptide; ICTP, type I collagen C-terminal 
telopeptide; PINP, procollagen type I N-terminal propeptide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
